Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Multimodal Glucose Prediction in Type 2 Diabetes

NCT: NCT07633171 · NOT_YET_RECRUITING

NCT IDNCT07633171
StatusNOT_YET_RECRUITING
Start Date2026-06-15
Completion2027-02-26
SponsorJohns Hopkins University (OTHER)
First posted
Last updated

Brief Summary

The primary objective of this research, funded by Samsung Strategic Alliance for Research and Technology, is to develop multi-modal foundation models that integrate Continuous Glucose Monitoring (CGM) data with patient behavior data (food intake, medication, and physical activity) to improve real-time glucose prediction and personalized diabetes management for patients with Type 2 diabetes (T2D), delivered via mobile apps and digital health tools.

Frequently Asked Questions

What is Multimodal Glucose Prediction in Type 2 Diabetes?

Multimodal Glucose Prediction in Type 2 Diabetes is a clinical trial registered under NCT07633171. Current status: NOT_YET_RECRUITING.

What is the status of NCT07633171?

The current status of NCT07633171 (Multimodal Glucose Prediction in Type 2 Diabetes) is: NOT_YET_RECRUITING.

When did Multimodal Glucose Prediction in Type 2 Diabetes start?

Multimodal Glucose Prediction in Type 2 Diabetes started on 2026-06-15.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.